Nano-hole induction by nanodiamond and nanoplatinum liquid, DPV576, reverses multidrug resistance in human myeloid leukemia (HL60/AR)

Alia Ghoneum1,2
Shivani Sharma1,3
James Gimzewski1,3
1Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, 2Department of Otolaryngology, Drew University of Medicine and Science, Los Angeles, 3California Nanosystems Institute (CNSI) at University of California, Los Angeles, Los Angeles, CA, USA

Abstract: Recently nanoparticles have been extensively studied and have proven to be a promising candidate for cancer treatment and diagnosis. In the current study, we examined the chemo-sensitizing activity of a mixture of nanodiamond (ND) and nanoplatinum (NP) solution known as DPV576, against multidrug-resistant (MDR) human myeloid leukemia (HL60/AR) and MDR-sensitive cells (HL60). Cancer cells were cultured with different concentrations of daunorubicin (DNR) (1 × 10−9–1 × 10−6 M) in the presence of selected concentrations of DPV576 (2.5%–10% v/v). Cancer cell survival was determined by MTT assay, drug accumulation by flow cytometry and confocal laser scanning microscopy (CLSM), and holes and structural changes by atomic force microscopy (AFM). Co-treatment of HL60/AR cells with DNR plus DPV576 resulted in the reduction of the IC50 to 1/4th. This was associated with increased incidences of holes inside the cells as compared with control untreated cells. On the other hand, HL60 cells did not show changes in their drug accumulation post-treatment with DPV576 and DNR. We conclude that DPV576 is an effective chemo-sensitizer as indicated by the reversal of HL60/AR cells to DNR and may represent a potential novel adjuvant for the treatment of chemo-resistant human myeloid leukemia.

Keywords: nanodiamond, nanoplatinum, daunorubicin, flow cytometry, AFM

Introduction
Nanoparticles have shown promising results for cancer therapies. Several studies have shown the success of drug delivery and cell targeting using nanoparticles. One example is the conjugation of trastuzumab (Herceptin®) to doxorubicin-carrying nanoparticles which allows transport of the chemotherapeutic agent specifically to tumor cells. In addition, antibody-conjugated nanoparticles have the potential to be used in active targeted drug delivery. Other nanoparticles that have been studied for their use in cancer therapies include: iron oxide, poly(D,L-lactide-co-glycolide)/montmorillonite, poly(D,L-lactic acid), nickel, and human serum albumin.

The development of multidrug resistance (MDR) to anticancer agents by tumor cells is a major obstacle in the chemotherapeutic cure of cancer. Therefore, larger dosages of these anticancer drugs must be applied, leading to increased toxicity; side effects include myelosuppression, carcinogenic effects, alopecia, myalgia, thrombocytopenia, congestive heart failure, and immune suppression. There are many drugs that have been shown to reverse MDR in MDR-associated protein (MRP), including: probenecid, an inhibitor of organic anion transport; genistein, an inhibitor of tyrosine kinase; buthionine sulfoximine, an inhibitor of glutathione synthesis; ethacrynic acid to reverse glutathione S-transferase-mediated resistance; and calcium channel blockers.
Earlier studies showed that a mixture of two nanoparticles – nanodiamond (ND) and nanoplatinum (NP) – in liquid form (DPV576) and in fabric form (DPV576-C), show immune modulatory effects. In the current study, we extend our research with DPV576 to examine its chemo-sensitizing activity against DNR-resistant human myeloid leukemia (HL60/AR) in vitro.

### Materials and methods

#### Tumor cell lines and culture conditions

Human multidrug-resistant (MDR) myeloid leukemia (HL60/AR) cells and MDR sensitive (HL60) cells were used in the present study. HL60/AR cells were kindly provided by Dr Gollapudi at the University of California (Irvine, CA, USA). HL60 cells were purchased from the American Tissue and Culture Collection (ATCC) (Manassas, VA, USA). Tumor cells were maintained in our laboratory in a complete medium (CM) that consisted of RPMI-1640, supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, and 100 µg/mL streptomycin, and penicillin.

#### Drugs and chemicals

DNR (1,10-phenanthroline, 450-µg/mL) and calmodulin inhibitors to reverse MDR. However, these agents have been shown to be toxic in humans when used at very high doses. These considerations prompted us to investigate a new modulator of MDR with lower toxicity. DNR and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma (St Louis, MO, USA). DPV576, a liquid mixture of nanodiamond (ND) and nanoplatinum (NP) solution was used. DPV576 was supplied by Venex Company (Atsugi, Kanagawa, Japan). The particle diameters of NP and ND were 10–20 nm and 100–200 nm, respectively and their final concentrations were 50 ng/mL NP and 5 µg/mL ND.

#### Drug sensitivity assay

Drug sensitivity was determined using a colorimetric MTT assay. This assay is based on the reduction of tetrazolium salt MTT by a mitochondrial dehydrogenase from a colorless to a blue-colored formazan product in viable cells that can be measured spectrometrically. The amount of formazan produced is proportional to the number of living cells. Cells (1 × 10⁴/well) were seeded in 96-well plates and cultured in triplicate in the presence or absence of various concentrations of DPV576 (2.5%–10% v/v) and with or without selected concentrations of DNR (1 × 10⁻⁹–1 × 10⁻⁶ M). The final volume of medium in each well after addition of DPV576 and/or DNR was 200 mL. The cultures were incubated at 37°C for 3 days, after which 50 µg of MTT was added to each well, and the cultures incubated for an additional 4 hours. The plates were centrifuged, the medium carefully removed, the formazan crystals solubilized with acid alcohol, and the plates read at 590 nm using an ELISA plate reader (Molecular Devices, Menlo Park, CA, USA). The 50% inhibitory concentration (IC₅₀) was determined as the drug concentration, which resulted in a 50% reduction in cell viability. The IC₅₀ was determined by plotting the logarithm of the drug concentration versus the survival rate of the treated cells.

#### Daunorubicin (DNR) accumulation

The accumulation into cells of DNR, a fluorescent compound, was studied by flow cytometry, as has been previously described. Briefly, cells were incubated in the presence or absence of DPV576 (2.5%–10% v/v) at 37°C for 15 minutes. DNR (2 µM) was then added to the cells, gently mixed, and incubated at 37°C for 45 minutes. Accumulation of DNR was measured by flow cytometry using a FACSscan (Becton Dickinson, Franklin Lakes, NJ, USA), the fluorescence intensity was recorded from histograms, and the data was expressed as mean fluorescence channel numbers (MFC).

#### AFM imaging

HL60/AR cells (0.5 × 10⁶) were cultured with DPV576 (10% v/v) for 24 hours then exposed to DNR (2 µM) for 45 minutes. Results were compared to those of cells treated with DNR alone and DPV576 alone. Cytospin preparations (Shandon Southern Institute, Sewickley, PA, USA) of cells under different treatment conditions were air dried, fixed in 100% MeOH for 5 minutes, and prepared for AFM studies. Dimension 5000 AFM (Veeco, Plainview, NY, USA) under contact mode was used to image the HL60/AR cells with OTESP silicon probes (Veeco). Topographic height images were recorded at 512 × 512 pixels at a scan rate of 0.8 Hz. Image processing was performed using SPIP Software (Image Metrology, Horsholm, Denmark). Usually an MLCT-AFM tip (with a ‘k’ value of 0.03 N/m) contributes to the broadening effect because of its specific geometry.

#### Confocal imaging

Confocal laser scanning microscopy (CLSM) was used to detect DNR accumulation for HL60/AR cells treated with DNR alone and DNR plus DPV576. Cytospin preparations, as mentioned above, were prepared for confocal imaging.
The CLSM was operated in reflectance mode using a 515 nm laser line.24

Hole/vacuole analysis using light microscopy of Giemsa-stained preparations
Morphological assessment of hole induction in HL60/AR cells by DPV576 treatment was conducted in Giemsa-stained cytospin preparations. HL60/AR cells (0.5 × 10^6) were cultured with DPV576 (10% v/v) for 24 hours then exposed to DNR (2 µM) for 45 minutes. The cells (0.3 × 10^5) were then treated with either DPV576, DNR, DPV576 plus DNR, or saline. Afterwards, the samples were centrifuged on slides at 200 g for 5 minutes using a cytospin cytocentrifuge. Slides were air dried, fixed in 100% MeOH for 5 minutes, and then stained with 4% Giemsa solution for 15 minutes as has been previously described.25

Statistical analysis
Statistical significance was determined by Student’s t-test. Differences were considered significant at the P < 0.05 level.

Results
The effects of DPV576 on the susceptibility of HL60/AR cancer cells to DNR were examined at the levels of both cell survival and drug accumulation.

HL60/AR cell survival
HL60/AR cells were cultured with DNR at different concentrations (1 × 10^{-9}–1 × 10^{-6} M) in the presence or absence of DPV576 for 3 days. Cell survival and IC_{50} values were then determined by MTT assay. Figure 1 shows that DNR, as expected, inhibited the survival of cancer cells in a dose-dependent manner and that the IC_{50} of DNR alone was 3.1 µM. However, when the cells were co-cultured with DPV576 plus DNR, we noticed a decrease in cell survival that was also dose dependent of DPV576 and maximized at 10% v/v. Subsequently, the IC_{50} was significantly reduced, reaching 0.8 µM at 10% v/v.

Drug accumulation
Flow cytometry
To determine if the observed DPV576-enhanced accumulation of DNR cytotoxicity in HL60/AR cells is related to an alteration in drug transport, we studied accumulation of DNR by flow cytometry. The results show that DPV576 at concentrations of 2.5%, 5%, and 10% v/v significantly enhances the accumulation of DNR in HL60/AR cells (Figure 2A and C). On the other hand, HL60 cells did not show changes in drug accumulation post-treatment with DPV576 and DNR (Figure 2B), suggesting that DPV576 had no significant effect on the accumulation of DNR in HL60 cells.

Confocal studies
HL60/AR cells treated with DNR in the presence and absence of DPV576 were examined by CLSM. Cells exposed to low concentrations of DNR alone showed very faint brightness (Figure 3A); similarly, cells treated with low and high doses of DNR also showed a faint brightness (Figure 3B and C).

![Figure 1](https://www.dovepress.com/)

**Figure 1** Effect of DPV576 on the reversal of DNR resistance in HL60/AR cells. Cancer cells (1 × 10^4 well^{-1}) were seeded in 96-well plates with DNR (1 × 10^{-9} to 1 × 10^{-6} M) and cultured in the presence or absence of various concentrations of DPV576 (2.5, 5, and 10% v/v) for 3 days. Cell survival was determined by MTT assay. Data represents the mean ± SD from three individual experiments, each in triplicate. The IC_{50} of DNR with DPV576 required 1/4th the amount of DNR as compared to the IC_{50} of DNR alone. Abbreviations: DNR, daunorubicin; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; IC_{50}, 50% inhibitory concentration.
However, hole formation is increased in the control (Figure 4A) and in DNR only treated cells. AFM studies were carried out to examine the hole formation in HL60/AR cells treated with DNR in the presence or absence of DPV576. Results show that hole formation is increased in HL60/AR cells treated with DNR in the presence or absence of DPV576. Forward and side scatter was used to exclude debris and dead cells. Ten thousand cells were acquired for analysis by flow cytometry, and is expressed as MFC number. (A) HL60/AR cells; (B) HL60 cells; (C) dot plot and histogram overlays of HL60/AR cells with and without DNR and DPV576. Forward and side scatter was used to exclude debris and dead cells. Notes: Data represent the mean ± SD of three experiments; *P < 0.05; **P < 0.001. Ten thousand cells were acquired for analysis by flow cytometry. Abbreviations: DNR, daunorubicin; MFC, mean fluorescence channel.

**AFM studies**

AFM studies were carried out to examine the hole formation in HL60/AR cells treated with DNR in the presence or absence of DPV576. Results show that hole formation is detected in the control (Figure 4A) and in DNR only treated cells (Figure 4B). However, hole formation is increased post-treatment with DPV576 (Figure 4C). On the other hand, for HL60/AR cells treated with DNR plus DPV576, AFM detected marked increases in the size and number of holes (Figure 4D–I). These holes ranged from 40–500 nm in depth, and 0.1–2.5 µm in diameter, and were situated in the cytoplasm and the nucleus. Contrast images of Figures 4D and 4E correspond to Figure 4G and H and regions in dark orange indicate the depth of the holes. Figure 4I shows an apoptotic HL60/AR cell with membrane blebbing.

**Discussion**

Several studies have shown promising results for the role of nanoparticles in the reversal of chemo/radio-sensitization in cancer cells. Nanoparticles loaded with chemotherapeutic drugs have been used to successfully deliver drugs to the cytoplasm, nucleus, and other specific organelles. For example, DNR-loaded magnetic nanoparticles of Fe₃O₄ can overcome MDR. In another study, nickel nanoparticles have shown increased cancer cell membrane permeability. However, the use of nanoparticles as DNR sensitizers has been of major concern due to their known toxicity. Exposure by inhalation to fine-grained nickel nanoparticles can cause cancer formation, illness, and in some cases, death. Cobalt nanoparticles have also been shown to display similar levels of toxicity and tumor formation.
Moreover, I

results of the current study show that DPV576 reverses MDR

modulation of murine T lymphocytes by a mixture of ND/

activation of human monocyte-derived dendritic cells

DPV576 has shown immune modulatory effects such as

phagocytosis of titanium particles by sarcoma L929 cells;43

elastic fibers by dermatofibroma cells;44 erythrocytes and

bacteria by adenocarcinomas;45,46 Candida albicans by

lymphatic tumor cells;47 and Saccharomyces cerevisiae by

human breast, oral, and colon cancer cells.48,49 Cancer cells

can also phagocytize other cells such as lymphocytes50,51 and

neutrophils.52 In addition, phagocytosis of one tumor cell by

another tumor cell has been reported53 and is referred to as

cannibalism. In the current study, we detected the presence

of holes in the control untreated HL60/AR cells (Figure 4A) via AFM, which may be attributed to their cannibalistic activity. Treatment with DPV576 increased hole formation in cells (Figure 4C) and showed a three-fold increase in the percentage of cells with multiple holes (≥4) as compared to control untreated cells (Figure 4A) and DNR only treated
cells (Figure 4B). However, HL60/AR cells co-treated with DPV576 plus DNR showed holes more frequent in number and which appeared larger in size, ranging from 40–500 nm in depth and 0.1–2.5 µm in diameter, and were situated in the cytoplasm and the nucleus (Figure 4D–I). AFM studies were further confirmed using CLSM imaging.

Another mechanism by which DPV576 might kill HL60/AR cells is through interference with MRP and drug transport via modulation of the transport function of MRP. MRP is a member of the ATP-binding cassette superfamily of membrane transport proteins and has been suggested to play a role in the reduction of drug accumulation. Normally, MDR cells overexpress P-glycoproteins (P-gp); using a nanoformulation of drugs is one way of bypassing the P-gp pumps. Since HL60/AR is a cell line that is known to overexpress MRP, the data suggests that DPV576 might induce HL60/AR cell apoptosis through interference with drug transport in addition to inducing holes in the cancer cell membrane.

Several studies suggest that DPV576 serves a dual purpose in the fight against cancer – in addition to its ability to induce holes in cancer cells, it has been shown to have an immune modulatory effect. Such properties of DPV576 make this agent advantageous over other nanoparticles.

**Conclusion**

This study strongly suggests that DPV576 reverses resistance in HL60/AR cells by increasing cellular DNR accumulation via a mechanism that may involve induction of holes in the cellular membrane. It should be investigated as a unique candidate for drug delivery and MDR therapy with less toxic effects.

**Acknowledgments**

The authors are greatly indebted to Dr Sastry Gollapudi, Professor of Immunology, Division of Basic and Clinical Immunology, University of California, Irvine, CA, USA, for assistance in revision of the manuscript. The authors would also like to thank Venex Company, Atsugi, Kanagawa, Japan, for providing DPV576. Confocal laser scanning microscope work was performed at the California Nanosystems Institute Advanced Light Microscopy/Spectroscopy Shared Resource Facility at the University of California, Los Angeles, supported with funding from the National Institutes of Health – National Center for Research Resources shared resources grant (CJX1-443835-WS-29646) and the National Science Foundation Major Research Instrumentation grant (CHE-0722519). Atomic force microscopy imaging was performed at Nano and Pico Characterization Lab at the California Nanosystems Institute.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


